ECONOMIC BURDEN OF CARDIOVASCULAR DISEASES IN THE RUSSIAN FEDERATION IN 2016
https://doi.org/10.20996/1819-6446-2018-14-2-156-166
Abstract
Aim. To evaluate the economic burden of cardiovascular diseases (CVD) in the Russian Federation (RF) in 2016, including the direct costs and the economic losses caused by reduced productivity.
Material and methods. Main data sources: data of the Federal state statistics service, data of state statistical reporting (forms №14, №141, №12 and №16-VN), and data of State Guarantee Program of Free Medical Care to the Citizens of the RF, statistical data of CVD, ischemic heart disease (IHD), myocardial infarction, cerebrovascular diseases, stroke. The direct medical costs were calculated based on the number of hospitalizations, including daycare center, emergency calls and outpatient visits due to CVD using the costs of the State Guarantee Program. The amount of disability benefits payments was calculated based on the number of disabled persons from each group and by the amount of the disability allowance. Indirect costs (economic losses) included a shortage of gross domestic product (GDP) due to premature mortality and disability in economically active age and loss of earnings due to temporary incapacity for work. The potential years of life lost (PYLL) were calculated using the number of life years not reached in economically active age due to premature death. Losses associated with premature mortality in the economically active age included unproduced GDP due to lost life years in the corresponding age group due to deaths from CVD, meaning the population’ employment rate. Statistical analysis was performed by Microsoft Excel 10.0.
Results. PYLL due to premature death from CVD – 4.5 million years of potential life in economically active age, mostly men (3.3 million PYLL). Among almost 50% of men PYLL were due to ischemic heart disease. Economic burden because of CVD in 2016 in the RF reached 2.7 trillion ₽, which is equivalent of 3.2% of GDP for this year. In the structure of burden among all blood circulatory system diseases, IHD was in the first place (over 1 trillion ₽). In the burden structure, direct costs were only 8.1%, losses in the economics – 91.9% of the total burden. In the cumulative burden of CVD, IHD determined as 39.8% (over a trillion ₽), cerebrovascular diseases – fifth part (560 billion ₽), strokes and heart attacks – 424 billion ₽ and 213.1 billion ₽, respectively.
Conclusion. The economic burden because of CVD in the RF in 2016 was 2.7 trillion ₽ (3.2% of GDP). Economic losses caused by premature mortality of people in economically active age prevailed in the structure of the burden (over 90%). Such the significant economic burden is a weighty argument for increasing investments in the prevention and treatment of CVD.
About the Authors
A. N. KontsevayaRussian Federation
Anna V. Kontsevaya – MD,Ph, Deputy Director for Scientific and Analytical Work
Petroverigsky per. 10, Moscow, 101990
O. M. Drapkina
Russian Federation
Oxana M. Drapkina – MD, PhD, Professo, Corresponding Member of the Russian Academy of Science; Director
Petroverigsky per. 10, Moscow, 101990
Yu. A. Balanova
Russian Federation
Yulia A. Balanova – MD, PhD, Leading Researcher, Laboratory of Economic Analysis of Epidemiological Research and Preventive Technologies, Department of Epidemiology of Chronic Non-Comunicable Diseases
Petroverigsky per. 10, Moscow, 101990
A. E. Imaeva
Russian Federation
Asia E. Imaeva – MD, PhD, Senior Researche, Department of Epidemiology of Chronic Non-Comunicable Diseases
Petroverigsky per. 10, Moscow, 101990
E. I. Suvorova
Russian Federation
Evgenia I. Suvorova – Junior Researcher, Laboratory of Economic Analysis of Epidemiological Research and Preventive Technologies, Department of Epidemiology of Chronic Non-Comunicable Diseases
Petroverigsky per. 10, Moscow, 101990
M. B. Khudyakov
Russian Federation
Mihail B. Khudyakov – Leading Engineer, Laboratory of Economic Analysis of Epidemiological Research and Preventive Technologies, Department of Epidemiology of Chronic Non-Comunicable Diseases
Petroverigsky per. 10, Moscow, 101990
References
1. Oganov R.G., Kontsevaya A.V., Kalinina A.M. State Economic Burden of Cardiovascular Diseases in the Russian Federation. Cardiovascular Therapy and Prevention. 2011;10(4):4-9. (In Russ.)
2. Saygitov R.T., Chulok A.A. Cardiovascular diseases in the context of Russia’s long-term socio-economic development priorities. Annals of the Russian academy of medical sciences 2015;70(3):286-99. (In Russ.)
3. Virtanen M., Ervasti J., Mittendorfer-Rutz E., Lallukka T. et al. Work disability before and after a major cardiovascular event: A ten-year study using nationwide medical and insurance registers. Scientific Reports. 2017;7(1):1142. doi:10.1038/s41598-017-01216-2.
4. Leal J., Luengo-Fernandez R., Gray A. et al. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J. 2006,27(13):1610-1619. doi:10.1093/eurheartj/ehi733.
5. National Institute for Health and Clinical Excellence. Statins for the prevention of cardiovascular events. Available at: https://www.nice.org.uk/guidance/ta94. Checked by Mar 24, 2018.
6. Mozaffarian D, Benjamin E.J., Go A.S. et al. Heart disease and stroke statistics-2016 update a report from the American Heart Association. Circulation. 2016;133(4):38-360. doi:10.1161/CIR.0000000000000350.
7. Centre for Economics and Business Research. The economic cost of cardiovascular disease from 20142020 in six European economies. London: CERB; 2014.
8. Tuppin P, Riviere S, Rigault A. et al. Prevalence and economic burden of cardiovascular diseases in France in 2013 according to the national health insurance scheme database. Archives of Cardiovascular Diseases. 2016;109(6-7):399-411. doi:10.1016/j.acvd.2016.01.011.
9. Yang L, Wu M, Cui B, Xu J. Economic burden of cardiovascular diseases in China. Expert Review of Pharmacoeconomics and Outcomes Research. 2008,8(4):349-356. doi:10.1586/14737167.8.4.349
10. Srivastava A., Mohanty S.K. Age and Sex Pattern of Cardiovascular Mortality, Hospitalisation and Associated Cost in India. PLoS One. 2013,8(5):e62134. doi:10.1371/journal.pone.0062134.
11. Walker I.F., Garbe F., Wright J. et al. The Economic Costs of Cardiovascular Disease, Diabetes Mellitus, and Associated Complications in South Asia: A Systematic Review. Value in Health Regional Issues. 2018;15:12-26. doi: 10.1016/j.vhri.2017.05.003.
12. Government Decision № 1382 of 19 December 2015 ≪On the Programme of State guarantees for providing citizens of the Russian Federation with free medical care for 2016≫. Available at: http://www.consultant.ru/document/cons_doc_LAW_191018/. Checked by Feb 08, 2018. (In Russ.)
13. Federal State Statistics Service. Public Health in Russia. 2017: Statistical Bulletin. M.: Rosstat; 2017. (In Russ.)
14. Government Decision N 220 of 22 March 2014 “On the adoption of the indexation factor of social pension since 1 April 2014”. Available at: http://base.garant.ru/70622990/#ixzz54L3z5RIz. Checked by: Jan 16, 2018. (In Russ.)
15. Letter No. 11-7 / 10 / 2-8080 of the Ministry of Health of the Russian Federation, ФФОМС № 13572 / 26-2 / and on 21.11.2017 "On methodological recommendations on how to pay for medical care from the means of compulsory medical insurance". Available at:http://www.consultant.ru/document/cons_doc_LAW_283654/. Checked by:Jan16,2018. (In Russ.)
16. The average size of pensions for disabled persons registered in the system of the Russian Federation pension fund. Available at: http://www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/population/disabilities/#. Checked by: Jan 16, 2018. (In Russ.)
17. Statistical Bulletin Labor and Employment in Russia. Moscow: Rosstat; 2017. (In Russ.)
18. WHO. Mortality Database 2014. Available at: http://www.who.int/healthinfo/statistics/mortality_rawdata/en/. Checked by Jan 10, 2018.
19. Russian database on fertility and mortality. Available at: http://demogr.nes.ru/ru/demogr_indicat/data_description. Checked by: Jan 16, 2018. (In Russ.)
20. Government Decision №192/323н/45н/113 of 10 April 2012 "On the approval of the methodology for calculating economic losses from mortality, morbidity and disability of the population". Available at:http://www.consultant.ru/document/cons_doc_LAW_129302/. Checked by: Jan 16, 2018. (In Russ.)
21. Muka T., Imo D., Jaspers L. et al. The global impact of non-communicable diseases on healthcare spending and national income: a systematic review. European Journal of Epidemiology. 2015;30(4):251-77. doi:10.1007/s10654-014-9984-2.
22. Arah O.A., Westert G.P., Delnoij D.M. et al. Health system outcomes and determinants amenable to public health in industrialized countries: A pooled, cross-sectional time series analysis. BMC Public Health. 2005;5(81):1-10. doi:10.1186/1471-2458-5-81.
23. Abegunde D.O., Mathers C.D., Adam T. et al. The burden and costs of chronic diseases in low-income and middle-income countries. Lancet. 2007;370(9603):1929-38. doi:10.1016/S01406736(07)61696-1.
24. Lakic D., Tasic L., Kos M. Economic burden of cardiovascular diseases in Serbia. Vojnosanitetski Pregled .2014;71(2):137-43. doi:10.2298/VSP1402137L.
25. Luengo-Fernandez R., Leal J., Gray A., Petersen S., Rayner M. Cost of cardiovascular diseases in the United Kingdom. Heart. 2006; 92(10):1384-9. doi: 10.1136/hrt.2005.072173.
Review
For citations:
Kontsevaya A.N., Drapkina O.M., Balanova Yu.A., Imaeva A.E., Suvorova E.I., Khudyakov M.B. ECONOMIC BURDEN OF CARDIOVASCULAR DISEASES IN THE RUSSIAN FEDERATION IN 2016. Rational Pharmacotherapy in Cardiology. 2018;14(2):156-166. https://doi.org/10.20996/1819-6446-2018-14-2-156-166